ANTINEOPLASTON TREATMENT FOR ADVANCED HEPATOCELLULAR-CARCINOMA

Antineoplaston A10 injection (antineoplaston A10 I) exhibited cystosta tic growth inhibition of human hepatocellular carcinoma (HCC) cells in vitro and showed minimum adverse effects in a phase I clinical trial. Advanced HCC is hard to control because the potent anticancer drugs o r embolizations easily induce hepatic failure. We review herein 2 case s of advanced HCC treated with antineoplaston A10 I. Both cases showed interesting responses to antineoplaston A10 I. One showed massive coa gulation necrosis of tumors after intraarterial infusion of antineopla ston A10 I and the other showed resolution of portal vein tumor thromb osis with systemic infusion of antineoplaston A10 I. The usefulness of antineoplaston A10 I in terminal staged HCC is discussed.